6. パーキンソン病
[臨床試験数:2,123,薬物数:2,046(DrugBank:324),標的遺伝子数:183,標的パスウェイ数:198

Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00108667
(ClinicalTrials.gov)
April 200515/4/2005Talampanel to Treat Parkinson's DiseaseAMPA Receptor Antagonist Treatment of Parkinson's DiseaseParkinson DiseaseDrug: IV Levodopa;Drug: TalampanelNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompletedN/AN/ABoth40Phase 2United States
2NCT00040209
(ClinicalTrials.gov)
June 200221/6/2002JP-1730 to Treat Parkinson's DiseaseAlpha-2 Adrenergic Antagonist Treatment of Parkinson's DiseaseParkinson DiseaseDrug: JP 1730;Drug: IV Levodopa;Drug: IV ApomorphineNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompletedN/AN/ABoth30Phase 2United States
3NCT00013624
(ClinicalTrials.gov)
March 200124/3/2001Riluzole to Treat Parkinson's DiseaseEffect of Antiglutamatergic Treatment in Parkinson's DiseaseParkinson's DiseaseDrug: IV LevodopaNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompletedN/AN/ABoth20Phase 2United States
4NCT00009048
(ClinicalTrials.gov)
January 200123/1/2001EMD 128130 for the Treatment of Parkinson's DiseaseEffect of Serotoninergic Treatment in Parkinson's DiseaseParkinson's DiseaseDrug: EMD 128130;Drug: IV LevodopaNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompletedN/AN/ABoth30Phase 2United States
5NCT00006337
(ClinicalTrials.gov)
October 20004/10/2000KW-6002 to Treat Parkinson's DiseaseAdenosine A2A Blockade With KW-6002 in Parkinson's DiseaseParkinson's DiseaseDrug: KW-6002;Drug: IV LevodopaNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompletedN/AN/ABoth16Phase 2United States